Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So cvm is sitting on a complete certified p3 study from last December and preparing analysis for public? Well then results are imminent. Last chance to get sub $3 shares then before arb win and p3 success.
No it needs 298 deaths to be complete
Page 9 of Ergomeds recently published 2017 annual report shows a graph of their partner pipeline. It shows Cel-Sci's phase 3 as almost finished.
Nice. No risk to common investor short term. Good to know.thanks.
You have a link to the vesting schedule?
Been no insider sales forms registered/posted. Not a one. They seem to think an arb win on horizon.
Insiders most likely exercised the 2.45s and appear to be holding per price action.
7 trading days left before last possible day to announce arb. 30 calendar so by next friday.
Cvm was at a low of $7 before it fell on fda hold. Which was lifted. Was trading $10 - $12 prior for a while (split adjusted). We are so close to arb, clinical trial is much further, peer p3 companies have much higher market caps, and outside sources are optimistic that p3 results are good. How we're paused below a 3 is odd to me in valuation.
Tender an offer for remaining shares they can't refuse and grab this company for what they spend on office supplies each year.
Merck should just buy into all the weakness. Take this over. Cheap fast move into a new drug.
New article. Seeking alpha says p3 most likely successful. https://seekingalpha.com/article/4170868-cel-sci-simple-math-appears-imply-phase-3-success
No they wouldn't hold back that news. Although think about this: they could be holding p3 results. What if an arb win and p3 success announced simultaneous? P3 certified all the way back in December. Current cro holds the data and they took a huge chunk of stock as payment for services.
Even the minimum win $50m+. Puts in solid footing to attract funds. Will be like armo or iova in terms of cash so therefore should have a similar valuation. The price gains are a true up of valuation.
With arb win should immediately be in $10 to $15 range. That's where cvm was split adjusted 2 to 3 years ago. Then it should move toward $45 over months pre p3 announcement. Post p3 success 60+. We're talking about cure for cancer folks. Destroying tumors. Not just prolonging life by 4 months as with a lot of other cancer drugs.
"The researchers found that it took less than four months after approval for the majority of eligible patients to receive treatment with at least one of the drugs."
https://medicalxpress.com/news/2018-05-cancer-immunotherapy-drugs-rapidly-patients.html
Daytraders may sit this rally out with the harsh exit yesterday. Ok by me. Would rather see investors rewarded. Karma if the flippers currently sitting on sidelines miss out.
Armo just bought out for 1.6b with only $49m cash on hand. Immuno is red hot right now.
Now we have the volumes to propel much higher. Good sign.
Cvm is buyout target on p3 success. At that point geert could possibly let it go as job well done. At least $50/share then.
Facility is 75k sq ft. Newish. They have patents for multikine in multiple countries. Ducks all lined. Careful planning by cvm to position correct for global distribution.
Geert said in presentation yesterday twice seeking "in excess of $50m." People have thrown around just $50m quite a bit. Cvm seems to be expecting more than that. Wouldn't be surprised if it's a $100m+.
Look at the valuation of iova. They have a similar drug. Just had a successful p2. Will take them years to get to p3. Losing money. . .at 1.4b valuation. There's no bag to get with stuck with. Even worse case arb isn't won a partnership will bring home win on p3.
I wouldn't want to be on sidelines when arb news randomly hits. I'd hate myself for collecting a nominal gain to try and swing trade then just to miss out on catapult. That's just me though. I'm holding through p3.
I agree. They were a billion $ company just on favorable p2. Didn't sell out then. The options are needed to increase insider holdings. Thwart a potential open market takeover. Cvm will be a huge threat to big biopharma with arb $ and existing scaleable facility.
Shark repellent. Those stock options at 2.45 means execs are uber confident in arb win. And possibly they know someone like merck is circling. Remember Merck said they're on the hunt for immunotherapy couple weeks ago.
Yeah this mm is bizarre. Glad to see someone else sees this.
We're going to explode higher. My guess is 50%+ in next couple days.
Agree near term. What will likely happen next is a major analyst will issue a $8+ price target. When arb $ comes in it will drive fund purchases. So big block buys will arrive. As we are a small amount of issued shares it will spike. I think this could be a billion $ company in the making. (1) have world class facility. (2) pending arb $ windfall. (3) p3 drug ready for approval with global patents. (4) more drugs in development. This could potentially run up to like $40 in a year. Immunotherapy hot. Merck issued active notice a week ago looking for partners in immunotherapy space.
Their facility is amazing. The arb $ will allow correct ramp into production of multikyne. Additional drugs in pipeline like flu and leaps will benefit immensely too. I'm hoping for punitive damages. Inventiv (cro) fumbled so badly that it risked amazing important drugs being brought to market. Link to 8k btw for closing arguments done:
https://fintel.io/doc/www.sec.gov/Archives/edgar/data/725363/000100487818000086/form8kcroarb4-18.txt
We are well below average pps/valuation of a p3 cancer company valuation. Arb $ will get them to production. Which is near. Market cap was $100m + even a couple years ago. How We're at $33m is baffling.
Don't give your shares up cheap. We're going much higher.
People at company will know anything first with water cooler talk. We'll see sharp moves up before any news.
I expect volatility
Cvm does candlestick patterns in intervals. This is one of them. Prob head to $4 on breakout day.
Lab is scaled and ready for prod. Arb and p3 fda and cvm ready to roll.
I think getting to 2.50 no problem before pr drops. Possible push to 3 before.
MM sucks. He writes down price 16 cents on 20k share volume. No wonder we trade so jagged.